Colestipol alone decreased LDL cholesterol by 23% (P<.001), while combination therapy with simvastatin decreased LDL cholesterol by 52% (P<.001) compared to baseline.
Does colestipol alone or combined with simvastatin improve lipid profiles and apolipoprotein B metabolism in male patients with moderate hypercholesterolemia and prior CABG?
The combination of colestipol and simvastatin significantly reduces total and LDL cholesterol through enhanced clearance of IDL and reduced total input of LDL.
p-value: p=< .001
The effects of colestipol therapy alone (20 g/d) or combined with simvastatin (20 mg/d) were examined in a group of eight male patients with primary moderate hypercholesterolemia (total cholesterol > or = 6.5 mmol/L > or = 250 mg/dL) who had undergone coronary artery bypass grafting more than 3 months previously. Colestipol therapy decreased total cholesterol by 14% (P < .001) and LDL cholesterol (LDL-C) by 23% (P < .001), while dual therapy decreased total cholesterol by 38% and LDL-C by 52% (both P < .001 versus baseline). No significant changes were observed in plasma triglyceride, VLDL cholesterol, or HDL cholesterol levels. VLDL subfraction turnovers were conducted at baseline and again on each regimen. ApoB kinetic parameters derived from a multicompartmental model suggested that colestipol therapy resulted in an expansion of the total VLDL apoB pool (36%, P < .05) that was largely due to a fall in the clearance rate of VLDL1 apoB (49%), while the LDL apoB pool decreased 23% as a result of diminished direct LDL input. The model used also revealed that addition of simvastatin to the resin therapy caused increases in the fractional transfer rates of VLDL2 to IDL and IDL to LDL together with a 37% increment in the LDL apoB fractional catabolic rate. Compared with baseline, combined therapy generated falls in both IDL (35%, P = .01) and LDL (37%, P < .04) apoB pools due to enhanced clearance of IDL (214%, P < .03) and reduced total input of LDL (39%, P < .003).
Gaw et al. (Thu,) conducted a other in Primary moderate hypercholesterolemia (n=8). Colestipol alone and in combination with simvastatin vs. Baseline was evaluated on Total cholesterol and LDL cholesterol (p=< .001). Colestipol alone decreased LDL cholesterol by 23% (P<.001), while combination therapy with simvastatin decreased LDL cholesterol by 52% (P<.001) compared to baseline.